Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Looking for high-upside stocks in 2025? AMD, UBER, and LLY each offer over 30% EPS growth potential and analyst-backed price targets with double-digit gains.
The stocks featured in this article have all approached their 52-week highs.
When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
When news broke that Johnson & Johnson was in talks to acquire Protagonist Therapeutics (NASDAQ:PTGX), the stock surged before trading was halted for volatility. Whether or not the deal closes, the signal to investors was unmistakable: peptides are back. Long viewed as hard to develop, lacking bioavailability when taken orally and more complex than biologics, they’ve proven their commercial power through GLP-1 blockbusters like Wegovy, Rybelsus and Zepbound - medicines that are now addressing a billion patients with major chronic metabolic conditions, and now dominate the multi billion dollar diabetes and weight-loss markets. In short, the advent of peptide therapeutics has been redefined.
As the financial markets gear up for the week commencing Monday, October 20, 2025, investors are keenly attuned to the insights of CNBC's Jim Cramer, a vocal and influential voice in the stock market. While a precise, real-time "Top 10" list from Cramer for this specific Monday is not publicly
The stocks featured in this article have all approached their 52-week highs.
When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
fell 3.5% in the afternoon session after political comments introduced significant uncertainty regarding the future pricing of the company’s weight-loss and diabetes drugs, Zepbound and Mounjaro.
The financial markets experienced a turbulent Friday, October 17, 2025, as the Dow Jones Industrial Average faced a downturn driven by a resurgence of fears within the banking sector. Concurrently, pharmaceutical giants Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) saw their shares plummet following a new round of
Eli Lilly shares are trading lower Friday, among other GLP-1 drug manufacturers, following Trump's comments that fat-loss drugs will be a lot lower in price.
